Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Teresa Graham
Biotech
Roche's obesity ambition not reliant on one megablockbuster
Roche’s head of metabolic development said the company is firing “on full cylinders” to get a phase 3 trial of its GLP-1/GIP drug launched next year.
James Waldron
Sep 23, 2025 7:45am
Roche drops HER2 bispecific, Xencor-partnered cytokine
Jan 30, 2025 4:56am
JPM25: Roche has $10B in M&A firepower per year, pharma CEO says
Jan 13, 2025 4:45pm
Roche refuses to disclose if TIGIT has failed again
Apr 26, 2023 11:17am
